CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Becton Dickinson Q4 revenue beats estimates on broad-based growth

By Reuters News


Overview

  • U.S. medical technology firm's fiscal Q4 revenue rose 5.4%, beating analyst expectations

  • Adjusted EPS for fiscal Q4 climbed 27%, beating analyst expectations

  • Company completed spin-off of Life Sciences business, focusing on core MedTech operations


Outlook

  • Company sees FY27 GAAP and FXN revenue growth in low single-digit percentage range

  • Becton Dickinson expects FY27 adjusted diluted EPS of $13.10 to $13.30


Result Drivers

  • SEGMENT GROWTH - Co reported broad-based revenue growth across Medical Essentials, BioPharma Systems and Interventional segments

  • PRODUCT LAUNCHES - Co highlighted new launches in pharmacy automation and vascular intervention as contributing to performance

  • SUPPLY CHAIN PARTNERSHIP - Co cited partnership with U.S. government to expand domestic manufacturing and supply chain resilience


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$5.27 bln

$5.11 bln (12 Analysts)

Q4 Adjusted EPS

Beat

$4.15

$4.07 (14 Analysts)

Q4 EPS

$2.52


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Becton Dickinson and Co is $205.00, about 2% above its November 4 closing price of $209.19

  • The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 12 three months ago


Reuters Recommended Reads

  • Nov 4 - Zimmer Biomet Q3 sales beat estimates, raises FY outlook

  • Nov 4 - UK's Smith & Nephew misses Q3 revenue estimates, cuts outlook on slower US orthopaedics market

  • Nov 4 - Edwards Lifesciences Q3 sales beat on TMTT portfolio adoption


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.